BMY's reported gross margin has expanded from roughly 55.7% in 2024Q2 to between 68% and 71% in 2026, suggesting a mix shift toward higher-margin products, yet quarterly revenue growth has decelerated to about 7% and EPS swings from $0.04 to $1.62 indicate earnings remain driven by non-operating or one-time items.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue of $13.1B in 2026Q3 with a 68.3% gross margin and 21.8% operating margin shows an improved structural profile, but operating margin volatility from 31.5% in 2026Q2 to 21.8% suggests profitability remains sensitive to non-recurring items.
The stock appears modestly undervalued, trading at about a 20% discount to fair value following its recent earnings release.
The bullish thesis highlights reliance on its pipeline, particularly Cobenfy, to offset revenue losses from expiring blockbusters.
Top institutional holder Vanguard owns 9.73% of the company, indicating strong institutional confidence.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | $1.35+22.7% vs $1.10 | $13.1B+2.7% vs $12.7B |
Q3 2026 Jul 30, 2026 | $2.04+27.5% vs $1.60 | $13.0B+10.5% vs $11.7B |
Q2 2026 Apr 30, 2026 | $1.58+11.3% vs $1.42 | $11.5B+5.1% vs $10.9B |
Q1 2026 Feb 5, 2026 | $1.26+2.4% vs $1.23 | $12.5B+1.8% vs $12.3B |
Bristol Myers Squibb is an established pharmaceutical powerhouse with a high-yield dividend and a focus on expanding its portfolio through strategic oncology alliances. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market while diversifying into gene editing and treatments for acute pain.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AHA--Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy for Camzyos.
A blockbuster blood thinner is about to lose $1.5 billion to $2 billion in sales, and the debt pile hasn't gone away. Retirees counting on Bristol Myers Squibb's payout need to know which numbers actually matter before 2027 arrives.
They are so much more than just dividend stocks.
Benchmark BMY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Bristol-Myers Squibb Company (BMY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $62.14 | $126.89B | 18.01 | -0.22% | 14.64% | 40.43% | 3.98% | |
| $29.39 | $167.51B | 21.61 | -1.65% | 6.34% | 4.59% | 5.85% | |
| $146.71 | $362.35B | 20.15 | 1.18% | 4.78% | 6.59% | 2.22% | |
| $291.31 | $514.68B | 122.92 | 8.57% | 15.68% | 286.66% | 2.26% | |
| $1354.00 | $1.28T | 59.00 | 44.7% | 31.9% | 83.64% | 0.44% | |
| $276.22 | $664.92B | 25.04 | 6.05% | 16.5% | 19.86% | 1.85% |
Bristol-Myers Squibb Company (BMY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Bristol-Myers Squibb Company (BMY) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Jul 30, 2026·SEC
May 8, 2026·SEC
Get notified when BMY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Bristol-Myers Squibb Company (BMY) stock FAQ — growth, dividends, profitability & financials explained
Bristol-Myers Squibb Company (BMY) reported $50.03B in revenue over the trailing twelve months. Revenue was $48.20B in fiscal year 2025. That is 220% more than the $15.06B of fiscal year 1996.
Bristol-Myers Squibb Company (BMY) revenue fell by 0.2% in fiscal year 2025, compared with the prior fiscal year.
Yes. Bristol-Myers Squibb Company (BMY) earned $9.24B in net income over the trailing twelve months (a 18.5% net margin).
Yes. Bristol-Myers Squibb Company (BMY) pays a dividend that yields 3.98% at the current price, a moderate yield.
Bristol-Myers Squibb Company (BMY) had a return on equity (ROE) of 40.4% in fiscal year 2025. That is well above the market's typical 10-15%.
Bristol-Myers Squibb Company (BMY) generated $9.29B in free cash flow over the trailing twelve months.
